Biological agents have been shown to be effective in controlling severe asthma. Omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab are all biological agents used to in routine practice in patients with severe asthma.
In the treatment of patients with severe asthma, a limited number of criteria are used to determine which biologic agent is more suitable for which patient. Total IgE, blood eosinophil count, and perineal allergen sensitivity are the current criteria considered in the use of biological treatments. With these limited criteria, some patients with severe asthma are still uncontrolled. The aim of this Research Topic is to explore new and existing clinical and laboratory features relevant in the selection of biological therapies in patients with severe asthma.
Suitable themes for manuscripts include, but are not limited to:
• Discovery of biomarkers for the identification of convenient biologicals in individuals with severe asthma
• Exploring which biomarker will be in the foreground in which patient
• Possible strategies to determine the most suitable biological agent in individual patients
• Patient-specific factors and novel therapeutic approaches to select the most effective biologic agent
• Factors triggering uncontrolled asthma during the use of biologicals
• Assessing the evidence on whether treating type 2 inflammation with biologicals is effective
• Exploring the evidence needed to decide to switch biologics in the presence of uncontrolled asthma
All article types accepted by Frontiers in Allergy are welcome.
Conflict of interest declaration from Dr. Breda Cushen: " I have received travel bursaries from Glaxosmithkline, Novartis and TEVA. I have given educational talks on behalf of Boehringer Ingelheim, Novartis and Astra Zeneca. I am/have been a principal and co-investigator on studies funded by Glaxosmithkline and Astra Zeneca which includes studies of anti-IL-5 therapies. I served as a moderator of the Irish Frontiers in Respiratory Medicine meeting hosted by Novartis"
Biological agents have been shown to be effective in controlling severe asthma. Omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab are all biological agents used to in routine practice in patients with severe asthma.
In the treatment of patients with severe asthma, a limited number of criteria are used to determine which biologic agent is more suitable for which patient. Total IgE, blood eosinophil count, and perineal allergen sensitivity are the current criteria considered in the use of biological treatments. With these limited criteria, some patients with severe asthma are still uncontrolled. The aim of this Research Topic is to explore new and existing clinical and laboratory features relevant in the selection of biological therapies in patients with severe asthma.
Suitable themes for manuscripts include, but are not limited to:
• Discovery of biomarkers for the identification of convenient biologicals in individuals with severe asthma
• Exploring which biomarker will be in the foreground in which patient
• Possible strategies to determine the most suitable biological agent in individual patients
• Patient-specific factors and novel therapeutic approaches to select the most effective biologic agent
• Factors triggering uncontrolled asthma during the use of biologicals
• Assessing the evidence on whether treating type 2 inflammation with biologicals is effective
• Exploring the evidence needed to decide to switch biologics in the presence of uncontrolled asthma
All article types accepted by Frontiers in Allergy are welcome.
Conflict of interest declaration from Dr. Breda Cushen: " I have received travel bursaries from Glaxosmithkline, Novartis and TEVA. I have given educational talks on behalf of Boehringer Ingelheim, Novartis and Astra Zeneca. I am/have been a principal and co-investigator on studies funded by Glaxosmithkline and Astra Zeneca which includes studies of anti-IL-5 therapies. I served as a moderator of the Irish Frontiers in Respiratory Medicine meeting hosted by Novartis"
